Verizon, Anheuser-Busch and Gilead Sciences are making headlines this morning before the opening bell. » Read More
AbbVie's quarterly net revenue jumped 17.8 percent, driven by demand for its top-selling treatment, Humira.
Drugmaker Merck& Co., focused heavily on its long-term future as it builds sales of crucial new medicines Keytruda for cancer and Zepatier for hepatitis C, still posted a big jump in second-quarter profit thanks to slightly higher sales and more cost cutting. The drugmaker is transitioning to a hoped-for new growth cycle fueled by those recently launched,...
Gilead Sciences Inc., down $7.50 to $81.05. McDonald's Corp., down $5.69 to $121.71. Texas Instruments Inc., up $5.20 to $71.42.
Some of the names on the move ahead of the open.
FOSTER CITY, Calif. _ Gilead Sciences Inc. on Monday reported second-quarter net income of $3.5 billion. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of $3.01 per share. Six analysts surveyed by Zacks expected $7.85 billion.
U.S. stocks closed lower in light volume trade Monday, with energy stocks lagging as oil prices briefly hit their lowest in nearly three months.
Though the biotech sector has had a sharp turnaround since mid June, is the worst really over? The "Fast Time Halftime Report" traders discuss whether or not its worth buying the biotech bounce.
U.S. stock-index futures indicated a mildly lower open Monday, after closing higher for a fourth consecutive week on Friday.
Big drug discoveries have been scant, but investors can find long-term value in some biotech names, said Mark Schoenebaum of Evercore ISI.
Mark Schoenebaum, Evercore ISI analyst, discusses his thoughts on the biotech rally.
U.S. Stocks closed higher Wednesday as Wall Street celebrated better-than-expected earnings off of a record week of gains for the Dow.
David Pearl, Epoch Investment Partners, and Tony Scherrer, Smead Capital Management, give their views on where investors can still find value in this record-breaking week for stocks.
Sarah Hunt, Alpine Funds Portfolio Manager, and Chris Retzler, Needham Growth Fund Portfolio Manager, discuss the momentum rally in U.S. stocks and give their picks.
Jim Cramer is concerned about Disney and says there’s reason you should be too even if you don’t own the stock.
Jim Cramer selected 10 market laggards that must bounce in order for the market to continue roaring higher.
Jim Cramer explained why takeover bids are a nasty surprise for the bears.
The iShares NASDAQ Biotechnology ETF was up more than 3 percent on the week, but down nearly 24 percent this year.
The "Fast Money" traders give you 4 trades in the biotech sector.
The Food and Drug Administration approved Gilead's drug for treating chronic hepatitis C virus infection.
The Fast Money traders share their final trades of the day.